Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q1 2026 Earnings Call Transcript
Operator: Good morning, and welcome to Fulcrum Therapeutics First Quarter 2026 Financial Results and Business Update Conference Call.
Fulcrum Therapeutics Inc. (FULC)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bailard Inc Thomas Bailard | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.52 | 50,945 | $179,326.40 | 7,080,945 | 2026-07-17 | Filing | |
| $3.56 | 116,671 | $415,348.76 | 7,030,000 | 2026-07-16 | Filing | |
| $3.56 | 107,377 | $382,262.12 | 6,913,329 | 2026-07-15 | Filing | |
| $3.58 | 75,952 | $271,908.16 | 6,805,952 | 2026-07-14 | Filing | |
| $3.56 | 53,651 | $190,997.56 | 6,730,000 | 2026-07-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.65 | 18,000 | $65,613.60 | 10,927 | 2026-06-26 | Filing | |
| $10.87 | 15,000 | $163,089.00 | 469,864 | 2026-01-02 | Filing | |
| $10.72 | 15,000 | $160,857.00 | 454,864 | 2026-02-02 | Filing | |
| $11.87 | 15,000 | $178,089.00 | 469,864 | 2026-01-02 | Filing | |
| $12.92 | 3,452 | $44,599.84 | 10,252 | 2025-12-15 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 835,204 | $3,056,847 | 0% | |
| 2. | 681,832 | $2,495,505 | 0.05% | |
| 3. | 285,798 | $1,046,021 | 0.71% | |
| 4. | 233,851 | $855,895 | 0.02% | |
| 5. | 153,794 | $562,886 | 0.01% |
News See All
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q4 2025 Earnings Call Transcript
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q4 2025 Earnings Call Transcript February 24, 2026Fulcrum Therapeutics, Inc. misses on earnings expectations.
Bullish Analyst Sentiment on Fulcrum Therapeutics (FULC) Following Positive Updates from Phase 1b PIONEER Study
Following encouraging updates from the ongoing Phase 1b PIONEER study evaluating pociredir in sickle cell disease, analyst sentiment around Fulcrum Therapeutics, Inc.
12 Best Multibagger Stocks to Buy Heading into 2026
As we head into 2026, the biggest question market participants are asking is whether the strong momentum this year can carry over into next year.
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q3 2025 Earnings Call Transcript
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q3 2025 Earnings Call Transcript October 29, 2025Fulcrum Therapeutics, Inc. misses on earnings expectations.
Fulcrum Therapeutics, Inc. (FULC): A Bull Case Theory
We came across a bullish thesis on Fulcrum Therapeutics, Inc. (FULC) on Stock Pursuit’s Substack. In this article, we will summarize the bulls’ thesis on FULC. Fulcrum Therapeutics, Inc.
Leerink Partners Upgrades Fulcrum Therapeutics, Inc. (FULC) to Outperform, Raises Price Target
On May 1, Fulcrum Therapeutics, Inc. (NASDAQ:FULC) provided business updates and reported results for the first quarter of fiscal 2025.
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q4 2024 Earnings Call Transcript
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q4 2024 Earnings Call Transcript February 25, 2025Fulcrum Therapeutics, Inc. misses on earnings expectations.
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q3 2024 Earnings Call Transcript
Operator: Good morning, and welcome to Fulcrum Therapeutics Third Quarter 2024 Financial Results and Business Update Conference Call. Currently, all participants are in a listen-only mode.
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q2 2024 Earnings Call Transcript
Operator: Good morning and welcome to Fulcrum's Therapeutics Second Quarter 2024 Financial Results and Business Update Conference Call. [Operator Instructions].
Hedge Fund Resource Center